Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children.

Pediatric Department I, University of Milan, Via Commenda 9, 20122 Milan, Italy.
International Journal of Antimicrobial Agents (Impact Factor: 4.42). 08/2002; 20(1):28-33. DOI: 10.1016/S0924-8579(02)00118-8
Source: PubMed

ABSTRACT A total of 384 children with group A beta-haemolytic streptococcal (GABHS) pharyngitis were randomized to receive either 40 mg/kg/day of cefaclor in two doses for 5 days (192 patients), or 40 mg/kg/day of amoxycillin in three doses for 10 days (192 patients). The signs and symptoms of pharyngitis were recorded and throat cultures were obtained at presentation and on days 6-7, 11-15, 16-20 and 28-35. Patient compliance was significantly higher in the children treated with cefaclor (100 vs. 95.1%; P = 0.003). At the end of follow-up, the percentage of clinical success was 91.4% for cefaclor and 91.9% for amoxycillin (P = 0.974); bacteriological success was obtained in 85.7 and 89.6% children (P = 0.348), respectively. Both treatments were well-tolerated with adverse event rates of 8.3% in the cefaclor group and 9.4% in the amoxcillin group (P = 0.857). Our study shows that five days' treatment with cefaclor is as effective and safe as the conventional 10-day course of amoxycillin in the treatment of GABHS pharyngitis, but compliance seems to be significantly greater.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The European Society for Clinical Microbiology and Infectious Diseases established the Sore Throat Guideline Group to write an updated guideline to diagnose and treat patients with acute sore throat. In diagnosis, Centor clinical scoring system or rapid antigen test can be helpful in targeting antibiotic use. The Centor scoring system can help to identify those patients who have higher likelihood of group A streptococcal infection. In patients with high likelihood of streptococcal infections (e.g. 3-4 Centor criteria) physicians can consider the use of rapid antigen test (RAT). If RAT is performed, throat culture is not necessary after a negative RAT for the diagnosis of group A streptococci. To treat sore throat, either ibuprofen or paracetamol are recommended for relief of acute sore throat symptoms. Zinc gluconate is not recommended to be used in sore throat. There is inconsistent evidence of herbal treatments and acupuncture as treatments for sore throat. Antibiotics should not be used in patients with less severe presentation of sore throat, e.g. 0-2 Centor criteria to relieve symptoms. Modest benefits of antibiotics, which have been observed in patients with 3-4 Centor criteria, have to be weighed against side effects, the effect of antibiotics on microbiota, increased antibacterial resistance, medicalisation and costs. The prevention of suppurative complications is not a specific indication for antibiotic therapy in sore throat. If antibiotics are indicated, penicillin V, twice or three times daily for 10 days is recommended. At the present, there is no evidence enough that indicates shorter treatment length.
    Clinical Microbiology and Infection 04/2012; 18 Suppl 1:1-28. · 4.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Current treatment guidelines from the Infectious Diseases Society of America, the American Heart Association, and the American Academy of Pediatrics recommend only oral penicillin V or intramuscular benzathine penicillin G as the drugs of choice for treatment of group A beta-hemolytic streptococcal (GABHS) pharyngitis. Ten-day treatment courses with 1st-generation oral cephalosporins or erythromycin are recommended as suitable alternatives in patients who are allergic to penicillin. Despite these recommendations, oral cephalosporins are used as drugs of choice for many patients with GABHS pharyngitis. Simpler and/or short-course regimens of cephalosporins that have been approved by the Food and Drug Administration offer alternatives with the potential for unchanged patient compliance. Increasing cephalosporin use in patients with GABHS pharyngitis has followed from numerous reports and metaanalyses of cephalosporin superiority over penicillin for bacteriologic eradication and clinical response. This review examines the evidence supporting the use of cephalosporins as a first choice of treatment for many patients with GABHS pharyngitis.
    Diagnostic Microbiology and Infectious Disease 04/2007; 57(3 Suppl):39S-45S. · 2.26 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality in haematopoietic stem cell transplant (HCT) recipients and patients with haematological malignancies. Early treatment initiation is vital for improving survival, but is hampered by difficulties in timely diagnosis. Prophylaxis with a broad-spectrum antifungal, such as voriconazole, has the potential to decrease the incidence of IFI in haematology patients. Based on a growing body of data, voriconazole appears to be effective for the primary and secondary prevention of IFIs in HCT recipients, with generally good tolerability.
    Clinical Microbiology and Infection 04/2012; 18 Suppl 2:1-15. · 4.58 Impact Factor

Full-text (2 Sources)

Available from
May 15, 2014